Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эндометриоз – сугубо хирургическая патология?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Применение комбинированных гормональных контрацептивов в профилактике заболевания и успешной борьбе с наиболее распространенными клиническими проявлениями эндометриоза, а именно с синдромом EAPP (endometriosis associated pelvic pain): хроническая тазовая боль, диспареуния и дисменорея, – перспективно для системы здравоохранения в отношении торможения прогрессирования заболевания, сокращения рецидивов после хирургического лечения, повышения качества жизни пациенток.
Ключевые слова: эндометриоз, гормоны, факторы роста, апоптоз, неоангиогенез, агонисты гонадотропных рилизинг-гормонов, комбинированные гормональные контрацептивы.
Ключевые слова: эндометриоз, гормоны, факторы роста, апоптоз, неоангиогенез, агонисты гонадотропных рилизинг-гормонов, комбинированные гормональные контрацептивы.
________________________________________________
The application of the combined hormonal contraceptives in the preventive maintenance of disease and the successful fight with the most common clinical manifestations of endometriosis, namely, with the syndrome EAPP (endometriosis associated pelvic pain): chronic pelvic pain, dispareunia and dysmenorrhea, it is promising for the system of public health with respect to braking the progression of disease, reduction of relapses after surgical treatment, an improvement in the quality of the life of patients.
Key words: endometriosis, hormones, the factors of growth,apoptosis, neoangiogenesis, the agonists of gonadotropic realising-hormones, the combined hormonal contraceptives.
Полный текст
Список литературы
1. Гинекология: национальное руководство. М.: ГЭОТАР-Медиа, 2007.
2. Meresman GF, Bilotas MA, Lombardi E et al. Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003; 18 (9): 1767–71.
3. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45–55.
4. Bilotas M, Baraсao RI, Buquet R et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod 2007; 22: 644–53.
5. Vu K, Greenspan DL, Wu TC et al. Cellular proliferation, estrogen receptor, progesteron receptor, and bcl-2 expression in GnRHagonist-treated uterine leiomyomas Hum Pathol 1998; 4: 359–63.
6. Schindler AE. Gonadotropin-releasing agonist for prevention of postorerative adhesions: an overview. Gynecol Endocrinol 2004; 19: 51–5.
7. Fedele L, Bianchi S, Zanconato G et al. Long-term follow-up after conservative surgery for rectovaginal endometriosis. Am J Obstet Gynecol 2004; 190: 1020–4.
8. Redwine DB, Wright JT. Laparoscopic treatment of complete obliteration of the cul-de-sac associated with endometriosis: long-term follow-up of en bloc resection. Fertil Steril 2001; 76: 358–65.
9. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
10. Osuga Y. Novel therapeutic strategies for endometriosis: a pathophysiological perspective. Gynecol Obstet Invest 2008; 66 (Suppl. 1): 3–9.
11. Ohyama Y, Miyamoto K, Minamino N et al. Isolation and identification of midkine and pleiotrophin in bovine follicular fluid. Mol Cell Endocrinol 1994; 105 (2): 203–8.
12. Inoh K, Muramatsu H, Ochiai K et al. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem Biophys Res Commun 2004; 317 (1): 108–13.
13. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health 2010; 6: 27–35.
14. Harada T, Momoeda M, Taketani Y et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, doubleblind, multicenter, controlled trial. Fertil Steril 2009; 91: 675–81.
15. Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222–31.
16. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169–78.
17. Strowitzki T, Marr J, Gerlinger C et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod Update 2010; 25: 633–41.
18. Kohler G, Faustmann T, Gerlinger C et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21–5.
19. Schindler A, Christensen B, Henkel A et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol 2006; 22: 9–17.
20. Базанов Г.А., Коненков В.И., Михайленко А.А., Покровский В.И. Руководство по клинической иммунологии и аллергологии, иммуногенетике, иммунофармакологии. Триада, 2005.
21. Балахонов А.В. Ошибки развития. СПб.: ЭЛБИ-СПб., 2001.
22. Полетаев А.Б., Алиева Ф., Мальцева Л.И. Иммунопатология беременности и здоровье ребенка. РМЖ. Мать и дитя. Акуш. и гинекол. 2010; 18 (4): 162–7.
23. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Изд-во РАМН, 2003.
24. Radhupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18 (10): 487–51.
25. Popova VS, Davidov AL. Variations levels of chorionic gonadotropinum in serum of the blood at patient with ectopic pregnancy. Materials of V International Congress on Reproductive Medicine 2011; p 187.
26. Ramezanzadeh F. BMC Women’s Health 2004; 4: 9.
27. Ziegler D. Minerva Ginecol 2011; 63: 365–73.
28. Chung HW, Wen Y, Choi EA et al. Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. Mol Hum Reprod 2002; 8 (4): 350–5.
2. Meresman GF, Bilotas MA, Lombardi E et al. Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003; 18 (9): 1767–71.
3. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45–55.
4. Bilotas M, Baraсao RI, Buquet R et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod 2007; 22: 644–53.
5. Vu K, Greenspan DL, Wu TC et al. Cellular proliferation, estrogen receptor, progesteron receptor, and bcl-2 expression in GnRHagonist-treated uterine leiomyomas Hum Pathol 1998; 4: 359–63.
6. Schindler AE. Gonadotropin-releasing agonist for prevention of postorerative adhesions: an overview. Gynecol Endocrinol 2004; 19: 51–5.
7. Fedele L, Bianchi S, Zanconato G et al. Long-term follow-up after conservative surgery for rectovaginal endometriosis. Am J Obstet Gynecol 2004; 190: 1020–4.
8. Redwine DB, Wright JT. Laparoscopic treatment of complete obliteration of the cul-de-sac associated with endometriosis: long-term follow-up of en bloc resection. Fertil Steril 2001; 76: 358–65.
9. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
10. Osuga Y. Novel therapeutic strategies for endometriosis: a pathophysiological perspective. Gynecol Obstet Invest 2008; 66 (Suppl. 1): 3–9.
11. Ohyama Y, Miyamoto K, Minamino N et al. Isolation and identification of midkine and pleiotrophin in bovine follicular fluid. Mol Cell Endocrinol 1994; 105 (2): 203–8.
12. Inoh K, Muramatsu H, Ochiai K et al. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem Biophys Res Commun 2004; 317 (1): 108–13.
13. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health 2010; 6: 27–35.
14. Harada T, Momoeda M, Taketani Y et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, doubleblind, multicenter, controlled trial. Fertil Steril 2009; 91: 675–81.
15. Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222–31.
16. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169–78.
17. Strowitzki T, Marr J, Gerlinger C et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod Update 2010; 25: 633–41.
18. Kohler G, Faustmann T, Gerlinger C et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21–5.
19. Schindler A, Christensen B, Henkel A et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol 2006; 22: 9–17.
20. Базанов Г.А., Коненков В.И., Михайленко А.А., Покровский В.И. Руководство по клинической иммунологии и аллергологии, иммуногенетике, иммунофармакологии. Триада, 2005.
21. Балахонов А.В. Ошибки развития. СПб.: ЭЛБИ-СПб., 2001.
22. Полетаев А.Б., Алиева Ф., Мальцева Л.И. Иммунопатология беременности и здоровье ребенка. РМЖ. Мать и дитя. Акуш. и гинекол. 2010; 18 (4): 162–7.
23. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Изд-во РАМН, 2003.
24. Radhupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18 (10): 487–51.
25. Popova VS, Davidov AL. Variations levels of chorionic gonadotropinum in serum of the blood at patient with ectopic pregnancy. Materials of V International Congress on Reproductive Medicine 2011; p 187.
26. Ramezanzadeh F. BMC Women’s Health 2004; 4: 9.
27. Ziegler D. Minerva Ginecol 2011; 63: 365–73.
28. Chung HW, Wen Y, Choi EA et al. Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. Mol Hum Reprod 2002; 8 (4): 350–5.
________________________________________________
1. Гинекология: национальное руководство. М.: ГЭОТАР-Медиа, 2007.
2. Meresman GF, Bilotas MA, Lombardi E et al. Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003; 18 (9): 1767–71.
3. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45–55.
4. Bilotas M, Baraсao RI, Buquet R et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod 2007; 22: 644–53.
5. Vu K, Greenspan DL, Wu TC et al. Cellular proliferation, estrogen receptor, progesteron receptor, and bcl-2 expression in GnRHagonist-treated uterine leiomyomas Hum Pathol 1998; 4: 359–63.
6. Schindler AE. Gonadotropin-releasing agonist for prevention of postorerative adhesions: an overview. Gynecol Endocrinol 2004; 19: 51–5.
7. Fedele L, Bianchi S, Zanconato G et al. Long-term follow-up after conservative surgery for rectovaginal endometriosis. Am J Obstet Gynecol 2004; 190: 1020–4.
8. Redwine DB, Wright JT. Laparoscopic treatment of complete obliteration of the cul-de-sac associated with endometriosis: long-term follow-up of en bloc resection. Fertil Steril 2001; 76: 358–65.
9. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
10. Osuga Y. Novel therapeutic strategies for endometriosis: a pathophysiological perspective. Gynecol Obstet Invest 2008; 66 (Suppl. 1): 3–9.
11. Ohyama Y, Miyamoto K, Minamino N et al. Isolation and identification of midkine and pleiotrophin in bovine follicular fluid. Mol Cell Endocrinol 1994; 105 (2): 203–8.
12. Inoh K, Muramatsu H, Ochiai K et al. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem Biophys Res Commun 2004; 317 (1): 108–13.
13. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health 2010; 6: 27–35.
14. Harada T, Momoeda M, Taketani Y et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, doubleblind, multicenter, controlled trial. Fertil Steril 2009; 91: 675–81.
15. Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222–31.
16. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169–78.
17. Strowitzki T, Marr J, Gerlinger C et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod Update 2010; 25: 633–41.
18. Kohler G, Faustmann T, Gerlinger C et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21–5.
19. Schindler A, Christensen B, Henkel A et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol 2006; 22: 9–17.
20. Базанов Г.А., Коненков В.И., Михайленко А.А., Покровский В.И. Руководство по клинической иммунологии и аллергологии, иммуногенетике, иммунофармакологии. Триада, 2005.
21. Балахонов А.В. Ошибки развития. СПб.: ЭЛБИ-СПб., 2001.
22. Полетаев А.Б., Алиева Ф., Мальцева Л.И. Иммунопатология беременности и здоровье ребенка. РМЖ. Мать и дитя. Акуш. и гинекол. 2010; 18 (4): 162–7.
23. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Изд-во РАМН, 2003.
24. Radhupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18 (10): 487–51.
25. Popova VS, Davidov AL. Variations levels of chorionic gonadotropinum in serum of the blood at patient with ectopic pregnancy. Materials of V International Congress on Reproductive Medicine 2011; p 187.
26. Ramezanzadeh F. BMC Women’s Health 2004; 4: 9.
27. Ziegler D. Minerva Ginecol 2011; 63: 365–73.
28. Chung HW, Wen Y, Choi EA et al. Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. Mol Hum Reprod 2002; 8 (4): 350–5.
Авторы
А.Л.Тихомиров
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
________________________________________________
A.L.Tikhomirov
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.